1st November, 2019
Labetalol 100mg/20ml Ampoules
The launch of Labetalol IV by Bowmed Ibisqus has brought necessary reinforcement of the UK supply chain for this critical hospital medicine following periods of shortage during 2019.
This is the first product to be brought to the UK market following our new distribution partnership with S.A.L.F. S.p.A. For over 90 years S.A.L.F. have brought essential medicines across a variety of therapeutic forms to the Italian market and we are excited to develop this new European partnership in the coming months and years.
This product follows the original and familiar product format of 100mg/20ml and is packaged in clear glass ampoules for ease of visual examination. The ampoules have been affixed with labels in a longitudinal manner so that the product details can be viewed in the same field of vision, in accordance with MHRA Best Practice guidelines. In addition, we have been able to avoid a plastic tray component in favour of a secure recyclable cardboard tray.
The product has been listed with AAH under order code LAB0138K. If you would like to discuss a pricing arrangement or stock availability for Labetalol IV or any of our other products, please contact us directly on +44 (0)845 6436 703 or email us
19th October, 2019
Hope House Chirk Dark Run
On the 19th October Chirk Castle was lit up along with the community of Chirk and surrounding areas during the Hope House Charity 5k Dark Run. Bowmed Ibisqus were delighted to be asked to sponsor this local event that is set to raise over £7,000 of essential funds.
The Dark Run is one of many events organised by the charity that provides support to families in need of Palliative care at home, in the community and at Hope House Oswestry and Ty Gobaith.
Hope House is a local charity founded by Caroline and Roger Peachey on March 4th, 1991 following the death of their third child Hope. Hope House work hard to ensure that children affected by life limiting conditions and their families can have the best possible quality of life with access to specialist care and bereavement support, when and where they need it.
The charity is working hard to raise £6.5 million this year and we wish them every success in reaching their goal!
15th July, 2019
Cyber Essentials Certification 2019
Bowmed Ibisqus is once again proud to announce that we have passed the Cyber Essentials assessment and been awarded the 2019 Cyber Essentials certificate by the National Cyber Security Centre.
Demonstrating our cyber and IT security measures to our private and NHS clients is a integral part of our corporate governance program and important to us, as suppliers of injectable medicines to the NHS
Industry Standard in Cyber Security
The Cyber Essentials Certification shows we have a level of technical control that is an essential defence against current cyber and IT threats and is a testament to Bowmed Ibisqus’ dedication to cyber security and data protection.
24th March, 2019
Proud moment for Emma passing the finishing line!
Bowmed Ibisqus was proud to support one of our valued colleagues when she took part in the London Landmarks half marathon on Sunday 24th March 2019.
Emma ran on behalf of the Genesis Research Trust and raised over £500. Emma has an incredible commitment to her own fitness and to the fitness journey of those around her. In her spare time, she has run community-based running projects and is working toward a recognised coaching qualification.
Speaking after the race Emma said, “It was truly an amazing experience and it has given me a taste for running the London Marathon now!”
More about Genesis Research Trust: Founded in 1978, based at Imperial College London, the Trust is the largest collaboration of reproductive health researchers in the UK. It is the only charity of its kind to lie consistently at the heart of original leading-edge research investigating why and how things can go wrong with conception, pregnancy and birth; delivering real evidence-based results for medical treatments and outcomes of worldwide significance. Click here to find out more about Genesis Research Trust.